Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women

References

• Asmar R, Benetos A, Topouchian J, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995;26:485–90
   PubMed Web of Science ®Google Scholar
• Thijssen DH, Black MA, Pyke KE, et al. Assessment of flow- mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011;300:H2–12
   PubMed Web of Science ®Google Scholar
• Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2004;24:571–6
   PubMed Web of Science ®Google Scholar
• Sumino H, Ichikawa S, Ohyama Y, et al. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. Am J Cardiol 2005;96:148–53
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Monteleone P, Vitale C, et al. Dydrogesterone does not reverse the effects of estradiol on endothelium- dependant vasodilation in postmenopausal women: a randomised clinical trial. Maturitas 2002;43:117–23
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Miyao M, Akishita M, et al. Effects of long-term and reduced-dose hormone replacement therapy on endothelial function and intima-media thickness in postmenopausal women. Menopause 2002;9:58–64
   PubMed Web of Science ®Google Scholar
• Sumino H, Ichikawa S, Kasama S, et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res 2005;28:579–84
   PubMed Web of Science ®Google Scholar
• Sumino H, Ichikawa S, Kasama S, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006;189:436–42
   PubMed Web of Science ®Google Scholar
• Miura S, Tanaka E, Mori A, et al. Hormone replacement therapy improves arterial stiffness in normotensive postmenopausal women. Maturitas 2003;45:293–8
   PubMed Web of Science ®Google Scholar
• Kawecka-Jaszcz K, Czarnecka D, Olszanecka A, Rajzer M, Jankowski P. The effect of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension. J Hum Hypertens 2002;16: 509–16
   PubMed Web of Science ®Google Scholar
• Birkhäuser MH, Panay N, Archer DF, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008;11:108–23
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939–53
   PubMed Web of Science ®Google Scholar
• Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra- low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120–31
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Durand G, Kahler E, Pertyński T. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas 2010;67:227–32
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Cappagli B, Ciaponi M, et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008;59:2–6
   PubMed Web of Science ®Google Scholar
• Honjo H, Taketani Y. Low-dose estradiol for climacteric symptoms in Japanese women: a randomized, controlled trial. Climacteric 2009;12:319–28
   PubMed Web of Science ®Google Scholar
• Mizunuma H, Taketani Y, Ohta H, et al. Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis. Climacteric 2010;13:72–83
   PubMed Web of Science ®Google Scholar
• Terauchi M, Honjo H, Mizunuma H, Aso T. Effects of oral estradiol and levonorgestrel on cardiovascular risk markers in postmenopausal women. Arch Gynecol Obstet 2012;285:1647–56
   PubMed Web of Science ®Google Scholar
• Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002;25: 359–64
   PubMed Web of Science ®Google Scholar
• Mares P, Dauzat M, Abramovici Y. Hormone replacement therapy with estradiol valerate and cyproterone acetate: effects on endothelium-dependent vasodilatation and arterial wall compliance. Maturitas 2002;42:45–53
   PubMed Web of Science ®Google Scholar
• Teede HJ, Liang YL, Kotsopoulos D, et al. A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. Clin Endocrinol (Oxf) 2001;55: 673–82
   PubMed Web of Science ®Google Scholar
• Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166:740–5
   PubMed Web of Science ®Google Scholar
• Villa P, Sagnella F, Perri C, et al. Low- and standard-estrogen dosage in oral therapy: dose-dependent effects on insulin and lipid metabolism in healthy postmenopausal women. Climacteric 2008;11:498–508
   PubMed Web of Science ®Google Scholar
• Godsland IF, Manassiev NA, Felton CV, et al. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. Clin Endocrinol (Oxf) 2004;60:541–9
   PubMed Web of Science ®Google Scholar
• Störk S, von Schacky C, Angerer P. The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 2002; 165:301–7
   PubMed Web of Science ®Google Scholar
• Simoncini T, Mannella P, Fornari L, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004;145:5745–56
   PubMed Web of Science ®Google Scholar
• Fu XD, Garibaldi S, Gopal S, et al. Dydrogesterone exerts endothelial anti-inflammatory actions decreasing expression of leukocyte adhesion molecules. Mol Hum Reprod 2012;18: 44–51
   PubMed Web of Science ®Google Scholar
• Seeger H, Mueck AO. Effects of dydrogesterone on the vascular system. Gynecol Endocrinol 2007;23(Suppl 1):2–8
   PubMedGoogle Scholar